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1. Introduction 
1.1 Overview of Drug Metabolizing Enzymes (DMEs) and transporters 
Drug metabolism can either lead to detoxification, bio-inactivation and/or elimination of 
the drug from the body. Metabolism can be broadly categorized into phases I and II. Phase I 
drug metabolizing enzymes (DMEs) primarily comprise of the Cytochrome (CYP) 450 
family of enzymes. CYP3A4 is the most common isoform expressed in human liver and 
intestine accounting for ~30-60% of CYPs (Nebert & Russell, 2002) More than 50% of the 
currently marketed drugs are metabolized by CYP3A4 in humans (Guengerich, 1999). Phase 
II metabolism consists of conjugation reactions forming polar metabolites leading to 
enhanced excretion. Phase II reactions include glucuronidation (Uridine 5'-diphospho-
glucuronosyltransferase, UGT) sulfation (Sulfotransferase, SULT), methylation 
(Methyltransferase), glutathione conjugation (Glutathione S-transferase, GST), etc. (Jancova 
et al., 2010; Meyer, 1996).   
Drug transporters play a central role in the absorption, distribution, metabolism and 
elimination (ADME) processes of xenobiotics across the cellular barriers. They are broadly 
classified into uptake and efflux transporters which facilitate drug disposition in or out of 
the cells (Mizuno et al., 2003). Major transporters include, but are not limited to: multidrug 
resistant gene/P-glycoprotein (MDR/P-gp), multidrug resistance associated protein (MRP1-
3), breast cancer resistance protein (BCRP), organic anion transporting peptides (OATPs) 
and organic cationic transporters (OCTs) (Mizuno et al., 2003; Mizuno & Sugiyama, 2002).  
1.2 Altered drug metabolism and transport in pathophysiological conditions  
Several studies have shown that drug metabolism and transport is disrupted during 
diseases and altered pathophysiological conditions primarily due to reductions in gene 
expression of these enzymes and transporters (Aitken et al., 2006; Kato, 1977). The 
transcription factors such as nuclear factor-κB (NF-κB), CAAT enhancer-binding protein 
(C/EBP) or nuclear transcription factor E2-related factor 2 (Nrf2) have been shown to 
regulate DME and transporter gene expression in vivo and in vitro (Gonzalez & Lee, 1996; 
Shen & Kong, 2009; Zordoky & El-Kadi, 2009). In addition to basal transcription factors, the 
xenobiotic nuclear receptors, pregnane X receptor (PXR), constitutive androstane receptor 
(CAR) heterodimerize  with  the central nuclear receptor, retinoid X receptor (RXR) ǂ to 
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regulate the expression of DME and transporter genes (Chen et al., 2004; Goodwin et al., 
2002; Kast et al., 2002; Xie, 2008). Furthermore, nuclear receptors such as peroxisome 
proliferator activated  receptor (PPAR), liver X receptor (LXR) or farsenoid X receptor (FXR) 
can also regulate DME and transporter gene expression (Xie, 2008). The orphan nuclear 
receptor, hepatocyte nuclear factor (HNF) 4ǂ can regulate the gene expression of PXR and 
CAR mediated xenobiotic induction of CYP3A4 (Tirona et al., 2003).  
Altered drug metabolism can lead to adverse drug reactions which account for ~10% of 
hospitalized cases (Deng et al., 2009; Maddox et al., 2010). However, due to underreporting, 
the actual incidences may be much higher (Lazarou et al., 1998., Pirmohamed et al., 2004). As 
early as 1960s, variations in drug metabolism were observed in patients or animals with 
diabetes (Dixon et al., 1961), cancer (Kato et al., 1963), hepatitis (Klotz et al., 1974; McHorse et 
al., 1974) or influenza (Kraemer et al., 1982). Changes in drug metabolism were also 
associated with a corresponding change in the pharmacodynamics (PD) of drugs (Dixon et 
al., 1961; Kato et al., 1968). These early studies prompted the researchers to study the 
alterations in DME and transporter gene expression and activity in pathophysiological 
conditions such as cancer, diabetes/obesity, rheumatoid arthritis (RA), non-alcoholic fatty 
liver disease (NAFLD) and cardiovascular diseases (CVDs) such as hypertension, heart 
failure, or stroke, etc. (Alkayed et al., 2002; Charles et al., 2006; Fisher et al., 2008; 2009a; 
2009b; Thum & Borlak, 2002). Overall, the readers of this chapter will benefit from the 
discussions of the changes in expression of DMEs and transporters, and 
pharmacokinetics/pharmacodynamics (PK/PD) of clinically relevant medications in 
different pathophysiological conditions.  
2. Infection and inflammation 
2.1 Bacterial infections 
2.1.1 Drug metabolizing enzymes 
Most of the studies on regulation on DMEs have been documented with gram-negative 
bacteria. Of clinical relevance, sepsis induced by cecal ligation and puncture (CLP) is the 
most frequently used model owing to its close resemblance in the progression and 
characteristics of human sepsis (Wichterman et al., 1980). In a CLP rat model, total hepatic 
microsomal CYP content and activities were significantly reduced (Godellas et al., 1995). 
Infection of pigs with the gram-negative respiratory pathogen, Actinobacillus 
pleuropneumoniae, led to decreased clearances of antipyrine, caffeine, and acetaminophen 24 
h after inoculation. This was further supported by decreased microsomal metabolism of 
several CYP-dependent substrates (Monshouwer et al., 1995). Another widely studied gram-
negative pathogen, Citrobacter rodentium, is a natural murine pathogen which produces 
similar colonic pathology on the intestinal cells of the host as seen after enteropathogenic 
Escherichia coli infections in humans (Higgins et al., 1999). The mRNA and protein levels of 
CYP4F18 and 2D9 were induced in a live mouse model of inflammatory bowel disease 
induced by C. rodentium (Chaluvadi et al., 2009). The rapid down-regulation of CYP2Cs and 
CYP3As after intraperitoneal (i.p) injection and CYP4As after oral injection of C. rodentium 
were quantitatively and qualitatively different, suggesting that the effects of oral infection 
are not due to bacterial translocation to the liver (Chaluvadi et al., 2009).  
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Although, gram-positive infections account for more than 50% of the total community 
acquired infections (Martin et al., 2003), very few studies have linked the effects of gram-
positive bacteria on regulation of DMEs. It was shown that in patients suffering from gram-
positive bacteremia such as Pseudomonas or Staphylococcus infections, an increase in volume 
of distribution (Vd) and dilution of antimicrobial agents in plasma and extracellular fluids 
may occur, which needs careful monitoring of the dosage regimen (Pinder et al., 2002). 
Listeriosis, caused by Listeria monocytogenes, is one of the most critical food-borne diseases in 
humans. L. monocytogenes induced CNS infection in rodents significantly down-regulated 
mRNA, protein and activity of hepatic CYPs (Garcia Del Busto Cano & Renton, 2003).  
The gram-negative bacterial component, lipopolysaccharide (LPS), and the gram-positive 
bacterial component, lipoteichoic acid (LTA), serve as sterile infection models by inducing 
inflammatory responses in animals (Ginsburg, 2002; Leemans et al., 2002). LPS can down-
regulate the expression and activity of key hepatic, intestinal and renal DMEs in several 
animal species such as mice, rats or rabbits (Ghose et al., 2008; Sewer et al., 1996). 
Interestingly, studies have that changes in CYP expression and activity is dependent on the 
route of administrate at same dose of LPS (Shimamoto et al., 1998). We recently showed that 
LTA significantly down-regulated the gene expression of several phase I and phase II DMEs 
in mice (Ghose et al., 2009).  
2.1.2 Drug transporters  
Changes in expression of drug transporters can have significant impact on the safety and 
efficacy of the drugs. LPS treatment of mice significantly down-regulated P-gp and Mrp2, 
major transporters involved in disposition of clinically relevant drugs such as colchicine, 
verapamil, daunorubicin, cyclosporin A and the abundant food-derived carcinogen 2-
amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) (Dietrich et al., 2001; Petrovic et al., 
2007). LPS-treated mice had significantly lower hepatic P-gp (30% of control) and increased 
P-gp expression in the kidney (140% controls) (Hartmann et al., 2001; 2005).  
2.1.3 PK/PD studies 
As early as 1980’s, it was shown that vaccination with the bacillus Calmette-Guerin (BCG) 
decreased clearance of theophylline in human volunteers (Gray et al., 1983). Altered PK was 
observed in other bacterial infections induced by Streptococcus pneumoniae (decreased 
antipyrine clearance) or Mycoplasma pulmonis (increased Tilmicosin plasma levels) (Modric et 
al., 1998; Sonne et al., 1985). LPS injections in animals and humans altered PK parameters 
such as maximum plasma concentration (Cmax, increase), area under the curve (AUC, 
increase), half-life (T1/2), Vd and clearance (CL, decrease) of several widely prescribed 
medications such as cisplatin, antipyrine, theophylline, hexobarbital, gentamicin and 
vancomycin (Gous et al., 1995; Hasegawa et al., 1994; Ishikawa et al., 1990; Shedlofsky et al., 
1994). PK changes of drugs during bacterial infection or inflammation can profoundly affect 
the PD as well. E.g. turpentine oil-injected mice had very high anti-tumor activity of 
gimatecan compared to the controls (Frapolli et al., 2010). On the other hand, several studies 
have shown that inflammation does not affect the PD of drugs. E.g. despite of very high 
plasma concentrations of the calcium channel blocker, verapmil, or potassium channel 
antagonists, sotalol or propranolol; no change in the PD was seen in inflamed animals 
(Guirguis & Jamali, 2003; Kulmatycki et al., 2001; Mayo et al., 2000). The authors concluded 
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this to be due to altered receptor-functioning or receptor-ligand binding exhibited by 
inflammation. Nevertheless, the above studies need further evaluations to delineate the 
disparities in altered drug metabolism caused by different bacterial infections or 
inflammation which has significant clinical implications for drug therapy in disease states. 
2.2 Viral infections 
2.2.1 Drug metabolizing enzymes 
Viral infections can also stimulate the immune system releasing various inflammatory 
mediators from the immune cells (Mannering & Deloria, 1986). A survey of the literature 
reveals numerous studies on the effect of viral infections such as mouse-adapted influenza 
virus (Corbett & Nettesheim, 1973), Newcastle disease virus (Singh & Renton, 1981), 
encephalomyocarditis virus (Renton, 1981), chronic active hepatitis and cirrhosis (Schoene et 
al., 1972; Wilkinson, 1997) and HIV infection (Lee et al., 1993) on alteration of gene 
expression and activity of DMEs and oxidative pathways in animals and humans. Decreased 
levels of hepatic CYP1A2 were detected in children suffering from upper respiratory tract 
viral infections during an influenza outbreak (Chang et al., 1978; Kraemer et al., 1982). With 
exceptions of CYP2D6 mRNA and CYP1A2 activity, other major CYPs such as CYP2C9, 
2C19, and 3A4 in HCV-infected PXB mice (chimeric mouse with human hepatocytes) were 
comparable to the non-infected controls (Kikuchi et al., 2010). Recombinant adenovirus 
injections in Sprague-Dawley rats led to significant down-regulation of renal CYP2E1 and 
hepatic CYP3A2 and CYP2C11 expression and activity, and induction of CYP4A protein 
expression (Callahan et al., 2005; Le et al., 2006).  
2.2.2 Drug transporters 
A recent study showed that HIV-type 1 viral envelope glycoprotein gp120 decreased P-gp 
and Mrp expression levels in rat astrocytes (Ronaldson & Bendayan, 2006). However, due to 
the fact that HIV infected patients are on highly active antiretroviral therapy (HAART) 
consisting of numerous drugs, both, induction and suppression of drug transporters in HIV 
infection are reported (Giraud et al., 2010). Polyinosinic/polycytidylic acid [poly (I:C)] is 
widely used as a model of in vivo viral-induced inflammation. Poly (I:C) can induce 
interferons (IFNs) and pro-inflammatory cytokines such as interleukin (IL)-6, IL-10, IL-12, 
and tumor necrosis factor (TNF)-ǂ. A significant down-regulation of key maternal hepatic 
and placental drug transporters and their endogenous substrates was observed upon i.p 
injection of poly (I:C) in pregnant rats (Petrovic & Piquette-Miller, 2010) However, Abcb1b 
(ATP-binding cassette sub-family B member 1) and Abcc3 (ATP-binding cassette sub-family 
C) were significantly induced. A recent study in PXB mice infected with hepatitis C virus 
(HCV) reported significantly higher expression of MRP4 and OATP2B1 and lower 
expression of OCT1 compared to non-infected mice (Kikuchi et al., 2010).   
2.2.3 PK/PD studies 
During the 1982 influenza B outbreak in King County, Washington, 11 children whose 
asthma had previously been controlled with a stable theophylline dose, developed 
theophylline toxicity on this same dose (Kraemer et al., 1982). These children had a 
significant decrease in CL and increase in T1/2 of theophylline. HIV infections could also 
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lead to altered PK of levofloxacin and fluconazole (Goodwin et al., 1994; Tett et al., 1995). 
End-stage liver disease, which is largely the result of HCV infection, now accounts for up to 
50% of deaths among persons with HIV-1 infection (Bica et al., 2001). A clinical study in 
HIV-HCV-coinfected patients showed significantly lower nelfinavir oral clearances in HIV+ 
and HCV+ patients with and without cirrhosis compared to HIV+ and HCV-negative 
patients (Regazzi et al., 2005). This presses the need for therapeutic drug monitoring in 
individualizing nelfinavir dosage in HIV-HCV-coinfected patients. In addition, an increase 
in AUC and Cmax of several anti-retrovirals are reported in HCV-infected patients with 
moderate liver impairment (Veronese et al., 2000; Wyles & Gerber, 2005). Other studies have 
also shown significantly higher AUC of docetaxel and reduced glomerular filtration rate, 
suggesting changes in renal CYP in rats injected with the recombinant adenovirus 
expressing ǃ-galactosidase (Le et al., 2006; Wonganan et al., 2009). On the contrary, 
significantly reduced Cmax and AUC of ceftiofur hydrochloride were observed in pigs 
infected with porcine reproductive and respiratory syndrome virus compared to the 
uninfected pigs (Tantituvanont et al., 2009).  
2.3 Mechanisms for altered drug metabolism in infections and inflammation 
Bacterial or viral infections lead to activation of Toll-like receptor (TLR) signaling pathway, 
which leads to the induction of pro-inflammatory cytokines, IL-1ǃ, IL-6 and TNF-ǂ in the 
immune cells. In the liver, TLRs are present on the cell surface of various immune cells (the 
resident macrophages or Kupffer cells) as well as the hepatocytes (Scott et al., 2009). Out of 
the 13 TLRs identified in mammals, TLR4 is activated by the gram-negative component, 
LPS, and TLR2 is activated by the gram-positive component, LTA (Aliprantis et al., 1999; 
Takeuchi et al., 1999). We and others have shown down-regulation of Cyp3a11 and P-gp in 
LPS sensitive TLR4 wild type (C3HeB/FeJ) mice could not be detected in TLR4-mutant 
(C3H/HeJ) mice (Ghose et al., 2008; Goralski et al., 2003; 2005). Recent data from our lab 
showed that down-regulation of gene expression of key hepatic phase I and phase II DMEs 
in TLR2+/+ mice by LTA was blocked in TLR2-/- mice (Ghose et al., 2009). We also observed 
that LTA down-regulated Mrp2, had no effect on Mrp3 and induced Mdr1b expression. 
Although, most of the studies have cited the role of Kupffer cell-derived TLRs in hepatic 
drug metabolism, we and others have also shown that LPS or LTA treatment of primary 
mouse hepatocytes can directly affect the DMEs via TLRs present on the hepatocytes, 
independent of cytokines (Ferrari et al., 2001; Ghose et al., 2011a). TLR-mediated signaling is 
initiated by the down-stream adaptor protein, Toll-interleukin 1 receptor domain containing 
adaptor protein (TIRAP) (Kagan & Medzhitov, 2006; O'Neill & Bowie, 2007). We showed 
that TIRAP was involved only in TLR2-mediated regulation of DME and transporter genes 
(Ghose et al., 2011a), and not by TLR4 (Ghose et al., 2008).  
Cytokines are involved in alteration of DMEs and transporters in vitro (Barker et al., 1992; 
Muntane-Relat et al., 1995). LPS-treatment of primary rat cocultures of hepatocytes and 
Kupffer cells significantly suppressed phenobarbital-mediated induction of CYP2B1 
(Milosevic et al., 1999). This decrease was associated with a 5-fold induction in TNF-ǂ 
released from the Kupffer cells in cocultures. In vitro studies with cytokine-treated rat or 
human hepatocytes led to decreased expression and activity of several drug transporters 
including efflux pumps such as P-gp,  MRP2, 3 and 4, and BCRP, sodium-taurocholate 
cotransporting polypeptide (NTCP), a major sinusoidal transporter handling bile acids, 
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uptake transporters such as OATP-B, OATP-C, and OATP-8 (Diao et al., 2010; Le Vee et al., 
2008; Lee & Piquette-Miller, 2003; Sukhai et al., 2000; Vee et al., 2009).  
However, recent evidence suggests cytokines may not be playing a major role in regulation 
of DMEs. Earlier studies in TNF-ǂ-/- and IL-6-/- knockout mice revealed that DMEs were still 
down-regulated (Warren et al., 1999; 2001). A recent study by Kinloch et al in 
TNFR1−/−, IL1R1−/− and Kupffer cell depleted mice showed that only TNF-ǂ, but not IL-1ǃ 
and Kupffer cells, was involved in regulation of CYP3A11 and 3A25 oral C. rodentium 
infection (Kinloch et al., 2011). In addition, we showed that although down-regulation of 
DMEs was blocked in LTA-treated TIRAP-/- mice, hepatic cytokine gene expression 
remained unchanged (Ghose et al., 2011a). 
Nitric oxide (NO), released from macrophages and hepatocytes during inflammation is also 
known to regulate DMEs (Morris & Billiar, 1994). However, contrasting results have been 
reported for the role of NO in regulation of DMEs in cytokine-treated primary rat 
hepatocytes (Carlson & Billings, 1996; Sewer & Morgan, 1997). IL-1ǃ and TNF-ǂ-mediated 
down-regulation of CYP protein was NO dependent, but not in IL-6 mediated down-
regulation (Carlson & Billings, 1996). NO was also shown to regulate the suppression of 
UGT activities in cytokine-treated hepatocytes (Monshouwer et al., 1996).  
Several studies have shown that inflammation-mediated activation of NF-κB plays a 
significant role in down-regulation of DMEs (Abdulla et al., 2005; Gilmore, 2006; Ke et al., 
2001). NF-κB can either indirectly regulate CYP gene expression through mutual 
repression between NF-κB and nuclear receptors, or can directly regulate CYP gene 
expression through binding to NF-κB response element in the promoter region of CYP 
genes (Pascussi et al., 2003). Interaction of NF-κB with nuclear receptors during 
pathophysiological conditions can alter expression of DMEs (Gu et al., 2006). 
Inflammation-mediated activation of mitogen activated protein kinase (MAPK), c-Jun-N-
terminal kinase (JNK), also regulates nuclear receptors and DMEs (Adam-Stitah et al., 
1999; Yu et al., 1999). Recent experiments in human gastric carcinoma and pancreatic 
carcinoma cell lines suggested a prominent role of JNK activation in down-regulation of 
P-gp protein expression (Zhou et al., 2006). However, further detailed studies using in 
vitro models such as cell lines or primary hepatocytes, and specific inhibitors of these cell 
signaling components will significantly contribute in understanding the mechanistic 
regulation of DMEs and transporters during inflammation.  
We speculate that down-regulation of nuclear receptors during inflammation might be 
involved in regulating the gene expression of DMEs and transporters in animal models 
(Ghose et al., 2004, 2008, 2009; Synold et al., 2001). We also showed that down-regulation of 
nuclear receptors by LPS in TLR4+/+ or by LTA in TLR2+/+ mice was blocked in TLR4 
mutant or TLR2-/- mice (Ghose et al., 2008, 2009, 2011a). On the contrary, mRNA and protein 
expression of several CYPs did not differ in PXR-/- or PPAR-/- mice treated with LPS 
(Richardson & Morgan, 2005). Similarly, it was shown that PXR was least important in 
regulating several efflux and uptake drug transporters using PXR wild type or PXR null mice 
treated with LPS (Teng & Piquette-Miller, 2005). However, the down-regulation of Bsep and 
Mrp2 mRNA in IL6-treated wild type mice was attenuated in the PXR null mice. Thus, 
involvement of nuclear receptors in inflammation-mediated regulation of DMEs and 
transporters may depend on the nature of the inflammatory stimuli.  
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3.1 Drug metabolizing enzymes 
Owing to the fact that, most anticancer drugs have a very low or narrow therapeutic index, 
alteration of DMEs can lead to life-threatening adverse drug reactions or increased risk of 
treatment failure in patients undergoing chemotherapy. Decreased hepatic microsomal 
DME activity was detected in tumor bearing rats with Walker carcinosarcoma 256, where 
impaired metabolism of hexobarbital, strychnine and meprobamate was observed (Kato et 
al., 1963). Due to difficulties in obtaining human liver tissue from cancer patients, an 
Engelbreth-Holm-Swarm (EHS) sarcoma mouse model bearing transgenic CYP3A4/lacZ 
gene was developed (Charles et al., 2006). Reduced hepatic levels of the transgene-derived ǃ-
galactosidase, as quantified by o-nitrophenyl-ǃ-D-galactopyranoside assay, and Cyp3a11 
mRNA and protein was observed in these mice (Charles et al., 2006). Tumors derived from 
the surface of the ovary account for the vast majority of ovarian tumors (approximately 
80%). Altered gene expression ratio of CYP3A4/ABCB1 (P-gp) in cancer cells grown from 
epithelial ovarian tumors had significant contribution in altering docetaxel disposition 
(DeLoia et al., 2008). On the other hand, there was no significant correlation in 
CYP2C8/ABCB1 ratio suggesting that paclitaxel disposition may require additional critical 
gene products. The expression of several phase II DMEs was also characterized in EHS 
tumor-bearing mice (Charles et al., 2006). Out of 8 GSTs studied, six were reduced and two 
unchanged; SULT1A1 was increased while SULT2A1 and UGT2B5 were reduced, and no 
change was observed in UGT1A7. Tamoxifen remains the first-line targeted treatment for 
the estrogen receptor ǂ-positive breast cancer patients and undergoes metabolism in the 
breast tissue which also consists of several DMEs (Williams & Phillips, 2000). In a study 
examining the role of methylation patterns of genes responsible for tamoxifen metabolism, 
higher methylation rate of N-acetyl transferase-1 (NAT1), a phase II DME gene, was 
observed in human breast cancer tissues compared to control breast tissues (Kim et al., 2010).  
3.2 Drug transporters 
Changes in the genetic variability in clinical specimens as well as over expression of ABC 
transporter family in tumors have been shown to play a critical role in multidrug resistance 
to several anticancer drugs (Hoffmeyer et al., 2000; Robinson et al., 1997; Yoh et al., 2004; 
Young et al., 1999). A recent study showed significant reductions in the mRNA levels 
of Mdr2, Mrp2, Mrp3, Ntcp, Oatp 2, bile salt export pump (Bsep), Bcrp, whereas Mdr1a and 
Oatp1 remained unchanged (Sharma et al., 2008).  
3.3 PK/PD studies 
Cancer-induced changes in the PK and PD profiles of several drugs have been documented 
since the late 1960s (Kato et al., 1968; Rosso et al., 1968, 1971). In a clinical study, the 
absorption rate constant, apparent Vd and serum CL of penbutolol (antihypertensive drug) 
were significantly reduced in the cancer group (Aguirre et al., 1996). PD effect (reduction in 
heart rate) of penbutolol did not vary statistically in respect to baseline values in cancer 
patients (Aguirre et al., 1996). Reduction in the metabolism of omeprazole (CYP2C19 
substrate) has also been observed in patients with advanced cancer (Williams et al., 2000). 
Reduced CYP3A expression resulted in >2 fold increase in the sleep time in tumor bearing 
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mice receiving the widely used sedative-hypnotic, midazolam, (CYP3A specific substrate) 
(Charles et al., 2006). 
3.4 Mechanisms of cancer-mediated altered drug metabolism  
Since the 1800s, it was observed that chronic inflammation is frequently associated with the 
onset and progression of various cancers (Balkwill & Mantovani, 2001). A strong association 
between cancer progression and induction of cytokines or acute phase reactive proteins in 
tumors is documented (Burke & Balkwill, 1996; Burke et al., 1996; Naylor et al., 1993). E.g. 
EHS tumor-bearing mice had significantly higher circulating plasma levels of IL-6 (25 
pg/ml) compared to the control mice (below detection limit). IL-6 mediated activation of 
JNK was also evident in EHS tumor-bearing mice, which again prompts the important role 
of JNK in regulation of DMEs. Studies have shown that TLR expression is enhanced in 
tumor cells lines (Yu & Chen, 2008). However, the role of TLRs in alteration of DMEs and 
transporters in cancer has never been investigated. 
The role of NF-κB activation in acute inflammation has been suggested in carcinogenesis 
(Karin et al., 2002; Lind et al., 2001). Cancer-mediated alteration of DMEs and transporters 
may possibly be regulated by over-expression of NF-κB. A recent study highlighted the role 
of extra hepatic malignancies in down-regulation of PXR and CAR in tumor-bearing mice 
(Kacevska et al., 2011). This study prompts to link the reduction in nuclear receptors with 
altered drug metabolism in cancer. However, additional studies with nuclear receptor 
knockout animal models with tumors will help identify their direct role in regulation of 
DMEs and transporters. Overall, all these studies imply that tumor-mediated inflammation 
may play an integral role in drug response and toxicity of various anticancer agents.  
4. Diabetes and obesity 
4.1 Drug metabolizing enzymes 
Another prevalent pathophysiological condition affecting millions of people in the world is 
the occurrence of diabetes and obesity. As per the latest statistical report, 366 million people 
in the world will have diabetes by 2030 (Wild et al., 2004). Dixon et al demonstrated that 
alloxan-induced diabetes decreased hexobarbital, chlorpromazine, and codeine metabolism 
in male rats (Dixon et al., 1961, 1963). Although, streptozotocin-induced diabetes in rats and 
hamsters significantly induced hepatic and renal CYP2E1 and 4A2 protein levels (Chen et 
al., 1996; Shimojo et al., 1993), suggesting altered metabolism of ketones and fatty acids in 
diabetes, hepatic CYP2E1 protein levels remained unchanged in streptozotocin-induced 
diabetic mice livers (Chen et al., 1996; Sakuma et al., 2001). A recent study showed 
differential effects of alloxan-induced diabetes on protein expression and activity of CYP2E1 
(increased) and CYP2B4 (decreased) in rabbits (Arinc et al., 2005). Altered gene expression of 
DMEs in genetically obese zucker fatty rats (reduction in CYP2B1/2 and Mrp3) and db/db 
mice (increase in CYP2B10) are also reported (Xiong et al., 2002; Yoshinari et al., 2006a). 
Studies have reported interesting results on DME gene and protein expression for different 
diet-induced obese (DIO) animal models. E.g. Although Cyp3a11 gene and protein 
expression were significantly reduced in both long term (12 weeks) and short term 
treatment (1 week) of high fat diet (HFD), Cyp2c9 gene expression was significantly reduced 
only in the short term HFD treatment (Yoshinari et al., 2006b). We recently showed that 
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mRNA levels of the phase II DMEs (Ugt1a1, Sult1a1, Sultn) were reduced ~30-60% in mice 
fed high-fat diet (HFD, 60% kcal fat for 14 weeks) compared to low fat diet (LFD, 10% kcal 
fat) mice (Ghose et al., 2011b). RNA levels of Cyp2e1 and Cyp1a2 were unaltered in HFD 
mice. These findings indicate that regulation of CYPs is dependent on the model of diabetes 
and obesity, and is tissue, isoform and species-specific. 
4.2 Drug transporters 
Streptozotocin treatment in rats increased hepatic levels of Mdr2, leading to increased 
phospholipid secretion into bile (van Waarde et al., 2002). Another study also showed that 
the hepatic expression of uptake transporters (Oatp1a1, 1a4, 1b2, 1a6, 2b1, and Ntcp) in 
diabetic mice decreased significantly compared to the wild type controls (Cheng et al., 2008). 
Our recent study showed no effect of high fat in DIO mice on gene expression of hepatic 
transporters (Mrp2 and 3, and Mdr1b) (Ghose et al., 2011b). 
4.3 PK/PD studies 
Obesity-associated alterations in phase II metabolism were reported in 1980’s. E.g. 
clearances of oxazepam and lorazepam, widely used benzodiazepines and excreted as 
glucuronide conjugates, were significantly increased in obese patients (Abernethy et al., 
1983). Similarly, increased metabolism of chlorzoxazone (CYP2E1 substrate) to 6-
hydroxychlorzoxazone was observed in obese individuals. This was attributed to increased 
CYP2E1 activity associated with obesity (O'Shea et al., 1994). Animal studies performed 
using a diabetes mellitus rat model (induced by alloxan or streptozotocin treatment) have 
reported altered PK of drugs such as acetaminophen, chlorzoxazone, theophylline, 
clarithromycin, furosemide, and methotrexate (Baek et al., 2006; Kim et al., 2005a, 2005b; 
Park et al., 1996, 1998; Watkins & Sherman, 1992). Although, no changes in PD of atracurium 
were reported in obese animals compared to lean control (Varin et al., 1990), triazolam-
induced sedation in obese humans increased significantly compared to normal weight men 
(Derry et al., 1995). We also observed similar disparities in the PD of midazolam, CYP3A 
substrate, (increased sleep time) and zoxazolamine, CYP2E1 substrate (no change) in DIO 
mice (Ghose et al., 2011b). This can be attributed to decrease in CYP3A and no change in 
CYP2E1 expression. Thus, the differential effects of obesity on PD of drugs may depend on 
the DME, or the drug or the target organ itself.  
4.4 Mechanisms of altered drug metabolism in diabetes/obesity 
The major pathophysiological manifestation in diabetes/obesity is characterized by low-
level chronic and local inflammation, such as release or over expression of TNF-ǂ and C-
reactive protein in adipose tissue (Hotamisligil et al., 1993; Wellen & Hotamisligil, 2005). 
However, the role of inflammation in regulation of DMEs and transporters in 
diabetes/obesity remains unclear. Hormonal regulation of DMEs in diabetes/obesity has 
also been addressed before (Thummel & Schenkman, 1990). Although an increase in mRNA 
or protein levels of CYP2E1 have been observed in obese patients (Lucas et al., 1998), db/db 
mice showed no such effects (Yoshinari et al., 2006a). This can possibly be due to 
hyperinsulinemia leading to a faster turnover (shorter CYP2E1 mRNA half-life) by insulin 
(De Waziers et al., 1995). Various studies have shown that phosphatidylinositol-3-kinase 
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(PI3K) signaling, using PI3K inhibitors, wortmannin and LY294002, ameliorated insulin-
mediated decrease in CYP2E1 and phase II enzymes (ǂ-GST) mRNA (Kim et al., 2006; Kim & 
Novak, 2007; Woodcroft et al., 2002).  
Interestingly, lower expression of CAR and CYP2B in obese Zucker rats and ~2 fold 
induction in obese and genetically diabetic mice (db/db) on HFD (Xiong et al., 2002; Yoshinari 
et al., 2006b) were reported. This discrepancy in obese Zucker rats and db/db mice in 
regulating expression profiles of CYPs and nuclear receptors can be explained by the 
difference in the position of mutation of leptin receptor gene (Chua et al., 1996; Lee et al., 
1996). We recently showed that expression of PXR and CAR; and protein levels of RXRǂ 
were significantly reduced in HFD mice (Ghose et al., 2011b). Thus, a complex set of 
processes including but not limited to cytokines, nuclear receptors, insulin sensitization or 
downstream signaling molecules, may regulate DMEs and transporters in diabetes/obesity. 
5. Non-alcoholic fatty liver disease  
5.1 Drug metabolizing enzymes 
Non-alcoholic fatty liver disease (NAFLD) is highly prevalent with an estimated world 
population between 14% and 24% being affected. NAFLD comprises of symptoms ranging 
from simple steatosis (fatty liver) to the more severe non-alcoholic steatohepatitis (NASH, 
fatty liver with infiltration of inflammatory cells) to progressive hepatic fibrosis and to 
cirrhosis (Reynaert et al., 2005). Alteration of hepatic CYP2E1 was first noted in humans with 
NASH (Weltman et al., 1998). Later studies have shown significant contribution of NAFLD 
(comprising of both, simple stage fatty liver as well as NASH) on expression and activity of 
DMEs in animals (Fisher et al., 2008, 2009a, 2009b). Similarly, in vitro studies in primary 
human or animal hepatocyte cell cultures from steatotic or non-steatotic livers showed a 
profound impact of steatosis on the metabolic functionality of hepatocytes (Donato et al., 
2007; Fisher et al., 2004; Gomez-Lechon et al., 2004). Significant reductions in CYP1A2, 2C9, 
2E1 and 3A4 activities in fat-overloaded hepatocytes were observed compared with 
control hepatocytes obtained from the same liver sample (Fisher et al., 2008).  
5.2 Drug transporters 
Decreased mRNA and protein expression of uptake transporters such as NTCP, OATP1a1, 
1a4, 1b2 and 2b1; and OAT 2 and 3 were observed in NAFLD (Fisher et al., 2009a).  
5.3 PK/PD studies 
Studies have shown interesting results with acetaminophen (APAP) PK in rats and humans 
with NAFLD. Children with NAFLD had significantly higher concentrations of APAP-
glucuronide (APAP-G) in serum and urine compared with controls, with no significant 
differences in PK of APAP among the 2 groups (Barshop et al., 2011). Another study showed 
that biliary concentrations of APAP-sulfate (APAP-S), APAP-G, and APAP-glutathione were 
reduced in MCD (methionine- and choline-deficient) rats (Lickteig et al., 2007a). However, 
plasma levels of APAP-G were also elevated in MCD rats, similar to that observed in children 
(Barshop et al., 2011). A clinical study evaluated the effect of NAFLD on PK of silymarin 
(Schrieber et al., 2008). The AUC0-24h for the sum of total silymarin flavonolignans was ~3-4 fold 
higher in patients with NAFLD (p<0.03), compared with healthy volunteers.  
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5.4 Mechanisms of altered drug metabolism in NAFLD 
Several mechanisms have been proposed for the effect of NAFLD on altered drug 
metabolism. Deposition of fat in human hepatocytes can lead to a marked impairment in 
CYP mRNA and activity (Donato et al., 2006). Fisher et al observed intense staining for IL-1ǃ 
in steatotic livers, indicating that experimental steatosis and NASH results in increased 
hepatocellular inflammation (Fisher et al., 2009a). Studies have shown ambiguous results on 
expression of nuclear receptors and transcription factors in NAFLD (Fisher et al., 2009b; 
Hardwick et al., 2010; Lickteig et al., 2007b). Except for PXR, which was significantly 
increased by 1.4 fold, the other nuclear receptors (AhR, CAR, PPARǂ and Nrf2) were not 
altered (Fisher et al., 2008). Therefore, various factors need to be taken into account for 
improved pharmacotherapy in patients with NAFLD.  
6. Cardiovascular disorders 
6.1 Drug metabolizing enzymes 
CYPs in humans are responsible for metabolizing a large number of cardiovascular 
medications, including ǃ-blockers, calcium channel blockers and angiotensin receptor 
antagonists (Abernethy & Flockhart, 2000). Alteration in DMEs could be of particular 
clinical relevance in patients with heart failure because these patients take more than 10 
medications on average. Although, not detected in the normal human heart, failing hearts 
expressed CYP11B1 and 11B2 (Young et al., 2001). Surprisingly, an up-regulation in CYP2J2, 
1B1, 2E1, 4A10 and 2F2 gene expression was reported in the failing heart (Tan et al., 2002). 
Increased cardiac CYP11B2 mRNA was associated with increased myocardial fibrosis and 
the severity of left ventricular dysfunction in patients with heart failure (Satoh et al., 2002). It 
was shown that the production of testosterone metabolites, including dihydrotestosterone 
and androstenedione, was significantly increased in hypertrophic human hearts (Thum & 
Borlak, 2002). Transient ischemic attacks (TIA) are risk factors for strokes.  A recent study 
showed that cerebral infarct size was reduced in TIA-preconditioned animals and CYP2C11 
mRNA and protein were coincidentally increased in the brain after experimentally induced 
TIA (Johnston, 2004). Genetic polymorphisms of DMEs are commonly associated with heart 
failure and hypertension (Kivisto et al., 2005). E.g. a study in Japanese subjects reported that 
CYP2C9 wild type carriers had lower systolic blood pressure after losartan (metabolizes to 
the active metabolite EXP3174) therapy than poor metabolizers (Sekino et al., 2003).  
6.2 Drug transporters 
A recent study demonstrated a selective disease-dependent regulation of the high-affinity 
carnitine transporter, OCTN2, in patients with dilated cardiomyopathy, whereas the other 
OCT(N)s were unaffected (Grube et al., 2011). 
6.3 PK/PD studies 
It was shown that lidocaine plasma clearance was significantly decreased in patients with 
cardiac failure and this was associated with decreased liver blood flow (Thomson et al., 
1971). Another group also observed reduced plasma clearance of lignocaine in patients 
suffering from myocardial infarction without cardiac failure (Prescott et al., 1976). Thus, the 
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mounting evidence for the effect of CVDs on DMEs and transporters needs to be extended 
for further PK/PD studies. 
6.4 Mechanisms of altered drug metabolism in CVDs 
Failing or hypertensive hearts are susceptible to infiltration by pro-inflammatory cytokines 
and reactive oxygen species induced by stress (Fliser et al., 2004). Studies have shown that 
increased circulating levels of TNF-ǂ and IL-6 in patients with congestive heart failure were 
inversely proportional to CYP2C19 and CYP1A2 activity (Frye et al., 2002). Similarly, down-
regulation of OCTN2 expression in patients with dilated cardiomyopathy inversely 
correlated with cardiac CD3+ T-cell count (Grube et al., 2011). In addition, cardiac cytokine 
release may affect OCTN2 expression during cardiomyopathy associated with 
inflammation.  
7. Rheumatoid Arthritis (RA) 
7.1 Drug metabolizing enzymes 
Rheumatic diseases are estimated to affect up to 1.1% of the world’s population (Harris, 
1980). Various studies have shown that gene expressions of DMEs are altered in adjuvant 
arthritis (AA) rats (Achira et al., 2002b, 2002c; Projean et al., 2005). Similarly, activities of 
CYP3A were significantly decreased in AA rats compared to control rats (Uno et al., 2007).  
7.2 Drug transporters 
Decreased activity of hepatic P-gp in the isolated perfused liver of AA rats was reported 
(Achira et al., 2002c; Uno et al., 2007). Decrease in P-gp activity corresponded with the 
decreased levels of Mdr1a mRNA and P-gp protein in AA rats.  
7.3 PK/PD studies 
PK/PD changes such as elevated plasma levels of acebutolol, cyclosporin A, propranolol 
and prolongation of sleep time with pentobarbital were observed in AA rats compared to 
normal rats (Dipasquale et al., 1974; Piquette-Miller & Jamali, 1992, 1993; Shibata et al., 1993). 
Based on these early observations, recent studies have also shown altered PK of 
methotrexate, T-5557 (novel anti-inflammatory agent) and doxorubicin in AA animals 
(Achira et al., 2002a, 2002b; 2002d). Although, a significant increase in the plasma 
concentrations of verapamil in rats and humans with underlying arthritis were reported, 
there were no changes in the PD of verapamil (prolongation of PR interval) (Mayo et al., 
2000; Sattari et al., 2003). This discrepancy was then attributed to a decrease in the receptor-
ligand affinity in inflammation (Laporte et al., 1998; Shore et al., 1997).  
7.4 Mechanisms of altered drug metabolism in RA 
AA animal models represent a systemic inflammatory disease with bone and cartilage 
changes similar to those observed in RA (Williams et al., 1992). Down-regulation of hepatic 
P-gp in AA rats was attributed to elevated levels of cytokines such as TNF-ǂ and IL-6 but 
not IL-1ǃ (Philippe et al., 1997). Similarly, increased plasma concentrations of drugs in AA 
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rats correlated with increased serum TNF-ǂ level (Sattari et al., 2003). Several in vitro and in 
vivo studies have shown up-regulation of NF-κB in RA and osteoarthritis (Handel et al., 
1995; Mor et al., 2005). It was recently demonstrated that PXR and CAR expression in small 
intestine was decreased in arthritis (Kawase et al., 2007b). In another study, bilirubin 
elimination was significantly decreased in collagen-induced arthritis (CIA) rats compared to 
normal rats (Kawase et al., 2007a), which was attributed to decreased expression of CAR in 
CIA rats. Thus, overall these studies imply that inflammatory pathways may be involved in 
the regulation of DMEs and transporters in arthritis.  
8. Conclusion 
A common theme of this chapter is that a multiplex of mechanisms are responsible for 
alterations of DMEs, transporters and PK/PD of drugs in different pathophysiological 
conditions. It is well-established that changes in gene expression of enzymes and 
transporters can lead to disruption in drug disposition in altered pathophysiological 
conditions including infection/inflammation, cancer, obesity, CVD, rheumatoid arthritis, 
etc. Studies show that induction of inflammatory mediators is an underlying factor common 
to all these pathophysiological conditions and may contribute to altered drug disposition in 
disease states. In addition, the generally accepted role of cytokines in alterations of DMEs 
and transporters needs further evaluation. We have established the involvement of Toll-like 
receptor signaling pathway in the regulation of DMEs and transporters, and our studies 
point to the role of cytokine-independent pathways in the liver. The role of transcription 
factors and nuclear receptors in the regulation of DMEs and transporters in disease states 
need further investigation. There is an urgent need to develop models for delineating the 
roles of individual inflammatory mediators or nuclear receptors in altered drug disposition 
in disease states. Understanding alterations of drug disposition in disease states is critical in 
predicting and preventing undesirable effects of clinically-relevant medications.  
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